Marinus Pharmaceuticals Inc represents values of innovation, patient-centricity, and scientific excellence. The company is dedicated to developing innovative therapies to improve the lives of patients suffering from neurological conditions. Marinus Pharmaceuticals Inc follows a corporate philosophy focused on advancing breakthrough treatments through rigorous research, clinical trials, and collaboration with healthcare professionals. With a strong commitment to patient care, Marinus Pharmaceuticals Inc aims to address unmet medical needs and deliver effective treatments that can make a meaningful difference in the lives of individuals with neurological disorders.

Marinus Pharmaceuticals Inc primarily operates in the United States.

Marinus Pharmaceuticals Inc has achieved significant milestones in its journey. Some notable accomplishments include the FDA approval of its drug, Ganaxolone, for the treatment of seizures in patients with CDKL5 deficiency disorder and PCDH19-related epilepsy. Additionally, the company has made great progress in clinical trials, demonstrating positive results in the treatment of postpartum depression and refractory status epilepticus. Marinus Pharmaceuticals has also expanded its pipeline, exploring the potential of Ganaxolone in various neurological and psychiatric conditions. With these remarkable achievements, Marinus Pharmaceuticals Inc continues to solidify its position as a leading innovator in the field of pharmaceuticals.

Marinus Pharmaceuticals Inc is a biopharmaceutical company specializing in the development of innovative therapeutics for epilepsy and neuropsychiatric disorders. Founded in 2003, the company is headquartered in Radnor, Pennsylvania. Marinus focuses on the advancement of its proprietary therapeutic platform which targets GABA receptors in the brain, aiming to offer solutions for unmet medical needs in epilepsy, postpartum depression, and other conditions. With a strong commitment to research and development, Marinus Pharmaceuticals has conducted extensive clinical trials to evaluate the efficacy and safety of its drug candidates. The company continues to strive towards improving the lives of patients and making significant contributions to the field of neuroscience.

Marinus Pharmaceuticals Inc faces competition from several key players in the market. Some of its main competitors include companies such as GW Pharmaceuticals, Zogenix Inc, and Sage Therapeutics. These companies operate within the pharmaceutical industry and develop products targeting similar therapeutic areas.

Marinus Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Marinus Pharmaceuticals Inc. revolves around the development and commercialization of innovative therapeutics for neurological disorders. The company focuses on creating novel medications that target the modulation of specific neurotransmitter systems. Marinus Pharmaceuticals Inc. conducts extensive research and clinical trials to evaluate the efficacy and safety of their potential drug candidates. By leveraging their expertise in neuroscience and drug discovery, the company aims to improve the lives of patients suffering from various neurological conditions. Marinus Pharmaceuticals Inc. strives to bring innovative treatments to market, addressing unmet medical needs and creating value for shareholders.

Marinus Pharmaceuticals의 P/E 비율은 -0.15입니다.

Marinus Pharmaceuticals의 P/S 비율은 0.44입니다.

Marinus Pharmaceuticals에 대한 AlleAktien 품질 점수는 6/10입니다.

예상되는 Marinus Pharmaceuticals 매출은 37.42 백만 USD입니다.

예상되는 Marinus Pharmaceuticals 이익은 -109.06 백만 USD입니다.

Marinus Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for the treatment of central nervous system disorders. The company is based in New Jersey, USA. The company's business model is centered around offering new therapeutic solutions for patients with severe neurological disorders. Its research and development efforts primarily focus on the effects of neurosteroids in alleviating symptoms of conditions such as epilepsy, depression, and schizophrenia. Marinus Pharmaceuticals currently offers two products: Ganaxolone and IV Ganaxolone, both of which are allosteric modulators of the GABAA receptor. These products have shown potential in treating conditions such as premenstrual dysphoric disorder and severe epileptic seizures, with clinical studies yielding promising results. The company collaborates with leading institutions and experts in epilepsy research and aims to expand its research and development activities in various areas of neurology to provide innovative solutions for patients with severe neurological disorders. The company maintains a strict approach to developing therapeutics and is committed to conducting thorough clinical research to ensure product safety and efficacy.

Marinus Pharmaceuticals은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Marinus Pharmaceuticals의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Marinus Pharmaceuticals의 ISIN은 US56854Q2003입니다.

Marinus Pharmaceuticals의 WKN은 A2QEUC입니다.

Marinus Pharmaceuticals의 티커는 MRNS입니다.

지난 12개월 동안 Marinus Pharmaceuticals은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Marinus Pharmaceuticals은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Marinus Pharmaceuticals의 현재 배당 수익률은 입니다.

Marinus Pharmaceuticals은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Marinus Pharmaceuticals은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Marinus Pharmaceuticals은 '건강' 섹터에 속합니다.

Marinus Pharmaceuticals의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Marinus Pharmaceuticals는 0 USD를 배당금으로 지급했습니다.

Marinus Pharmaceuticals의 배당금은 USD에 지급됩니다.